Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-304-8
CAS number: 80-73-9
28-day repeated dose toxicity (HRC, 1989)
28-day repeated dose toxicity NOAEL(oral) = 30 mg/kg bw/day
28-day repeated dose toxicity (Biosafety researc Centre, 2011)
28-day repeated dose toxicity NOAEL(oral) = 20 mg/kg bw/day
The repeated dose toxicity of the test material was investigated in a
GLP study which was conducted accoding to a methodology similar to the
standardised guideline OECD 407.
During the study, groups of rats received DMI, formulated as a solution,
at dose levels of 6, 30 and 150 mg/kg bw/day, daily, for a period of 28
consecutive days, by oral gavage. Clinical findings, bodyweight changes,
food consumption, haematology parameters, biochemistry parameters and
urinalayses were conducted throughout the study. Following treatment on
day 28, the animals were sacrificed. Organs were weighed and macroscopic
and microscopic pathology investigation ensued.
Under the conditions of the study, the No Observed Adverse Effect Level
(NOAEL) of DMI for the males was judged to be 30 mg/kg/day each in the
conditions of this study because of the effects on the testis and
epididymis of the150 mg/kg group.
The repeated dose toxicity of the substance was investigated in a study
which was conducted under GLP conditions and in accordance with the
standardised guideline OECD 422.
During the study the test material was administered at 0 (treated with
the solvent, water for injection, only), 4, 20 or 100 mg/kg/day by
gavage to rats from 14 days prior to mating to the end of the 14-day
mating period. Males were further dosed for 14 days from the end of the
mating period. Daily dosing of the parental females continued
throughout pregnancy and up to day 4 of lactation period. Five males
from the main groups and an additional 5 females (satellite groups) were
used for the observation of reversibility for 14 days post treatment.
Parameters evaluated included clinical signs, bodyweight changes, food
consumption, urinanalysis, blood biochemistry, haematology, functional
observational battery examination. Following sacrifice, organ weights
were recorded gross pathology and histopathology examinations were
Under the conditions of the study no males or females were dead or
moribund. The given test material did not affect the general
conditions, including the detailed observation in the FOB.
During the dosing period, gains in the body weight were lower or tended
to be lower in the males and females of the 100 mg/kg group. However,
the body weight gains were higher during the recovery period.
Therefore, the given test material showed a tendency to reduce the body
weight gain and a tendency to recovery of the weight gain by the
withdrawal was seen.
As an effect on the food consumption, the mean daily food consumption of
female 100 mg/kg group was lower during the lactation period.
In the haematological examination of the female 100 mg/kg group,
haematocrit, haemoglobin and red blood cell count were higher and
reticulocyte ratio tended to be lower on day 5 of lactation.
In the blood chemical examination of the male 100 mg/kg group,
triglyceride and total cholesterol were higher or tended to be
higher. Moreover, total protein was lower in the female 100 mg/kg group
on day 5 of lactation.
In the serum protein electrophoresis of the female 100 mg/kg group on
day 5 of lactation, the concentrations and ratios of albumin and
gamma-globulin fractions and A/G ratio were lower, and the ratio of
beta-globulin fraction was higher.
Pathological examination revealed a macroscopical change as atrophy of
testis and epididymis in the male 100 mg/kg group. Also, the weights of
these organs were lower in the same group. These changes are considered
to be caused by the dosing of test substance. As the histopathological
findings, atrophy and vacuolation of seminiferous tubule, multinucleated
giant cell formation and interstitial cell hyperplasia were observed in
testis in the male 100 mg/kg group. In addition, at the end of the
recovery period, Sertoli cell-only syndrome (the finding which shows
that most reproductive cells disappeared and only Sertoli cells remain
in the seminiferous tubule) was found in the testis. At the end of the
dosing period, decrease of sperm and cell debris in the lumen were found
in the epididymis. At the end of the recovery period, decrease of sperm
was found in the epididymis. In females, the spleen weight was lower in
the 100 mg/kg group. However, no histopathological changes which were
considered to be caused by the dosing of test material were found.
Therefore, under the conditions of the study, the No Observed Adverse
Effect Level was considered to be 20 mg/kg bw/day
28-day repeated dosie toxicity (HRC, 1989)
The registered substance does not meet the criteria for classification
for Specific Target Organ Toxicity - Repeated Exposure (STOT-RE)
according to the EU Classification, Labelling and Packaging of
Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again